IL-1β and Allergy: Focusing on Its Role in Allergic Rhinitis

Table 2

Clinical test results and clinical applications of IL-1β.

Sample	Age (years)	Numbers (AR)	Sample source	Expression of IL-1β (pg/ml)		Clinical application	References
				Control	AR
Children	6-10	292 (210)	Serum	0.13-0.69 (0. 23)	11.07-15.08 (13.42)	It is considered in the article as a significant predictor of the risk of moderate to severe AR	Han et al., [88]
	6-12	116 (116)	Blood	Unknown		It is considered in the article as a significant predictor of the risk of moderate to severe AR	Han et al., [91]
Adults	21-29	12 (12)	Nasal secretions	Unknown	0.7-11.6 (8.0)	It is considered in the article that it can act as a signature factor for AR inflammation	Wagenmann et al., [11]
	Unknown	10 (10)	Nasal secretions	Unknown	19.5	It is used in the article as an indicator for assessing the efficacy of AR drugs	Weido et al., [13]
	20-49	20 (10)	Nasal lavage fluids			It is suggested in the article that it can be an index of the extent of neutrophil involvement in AR	Månsson et al., [57]
	Unknown	Unknown	Nasal secretions			It is used in the article as a distinguishing factor between AR and control	Bachert et al., [85]
	20-41	8 (4)	Serum			It is considered in the article that it can act as a signature factor for AR inflammation	Krouse et al., [90]
	15-66	41 (20)	Sera	0-412 (30)	3-996 (18)	It is used in the article as a distinguishing factor between AR and control	Gröger et al., [92]
		137 (89)	Nasal fluid	4-1000 (20)	2-7894 (32)	It is considered in the article that it can act as a signature factor for AR inflammation	König et al., [93]
		115 (85)	Plasma	Undetected-0.2 (0.13)	Undetected-1.72 (0.122)	It is used in the article as an indicator for assessing the efficacy of AR drugs	Bocşan et al., [94]